{"filing":{"accession_number":"0001213900-26-101636","cik":"0001611747","ticker":"SCNI","company_name":"Scinai Immunotherapeutics Ltd.","form":"6-K","filing_date":"2026-09-21","report_date":"2026-09-21","primary_document":"ea0306058-6k_scinai.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1611747/000121390026101636/ea0306058-6k_scinai.htm"},"events":[{"id":33853,"run_id":31156,"accession_number":"0001213900-26-101636","anchor_item_number":"EX-99.1","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"summary":"The press release announces that Scinai has regained compliance with Nasdaq's $1.00 minimum bid price requirement (Listing Rule 5550(a)(2)) after previously failing to maintain that threshold on March 12, 2026. The company's ADSs had fallen below $1.00 for 30 consecutive business days, triggering a delisting risk notice. This disclosure directly addresses a continued listing rule violation and its resolution, which is material to investors assessing the registrant's ability to remain listed on Nasdaq.","company_name":"Scinai Immunotherapeutics Ltd.","ticker":"SCNI","filing_date":"2026-09-21","form":"6-K","submitted_at":null,"items":[{"id":37414,"accession_number":"0001213900-26-101636","item_number":"EX-99.1","item_title":"ea030605801ex99-1.htm","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The press release announces that Scinai has regained compliance with Nasdaq's $1.00 minimum bid price requirement (Listing Rule 5550(a)(2)) after previously failing to maintain that threshold on March 12, 2026. The company's ADSs had fallen below $1.00 for 30 consecutive business days, triggering a delisting risk notice. This disclosure directly addresses a continued listing rule violation and its resolution, which is material to investors assessing the registrant's ability to remain listed on Nasdaq.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-21T11:01:29.467645+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37414,"accession_number":"0001213900-26-101636","item_number":"EX-99.1","item_title":"ea030605801ex99-1.htm","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The press release announces that Scinai has regained compliance with Nasdaq's $1.00 minimum bid price requirement (Listing Rule 5550(a)(2)) after previously failing to maintain that threshold on March 12, 2026. The company's ADSs had fallen below $1.00 for 30 consecutive business days, triggering a delisting risk notice. This disclosure directly addresses a continued listing rule violation and its resolution, which is material to investors assessing the registrant's ability to remain listed on Nasdaq.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-21T11:01:29.467645+00:00","company_name":"Scinai Immunotherapeutics Ltd.","ticker":"SCNI","filing_date":"2026-09-21"}]}